Face-to-face with Abingworth's Stephen Bunting:we've had time to adapt to tough markets
This article was originally published in Scrip
While many venture capital (VC) firms have dropped beneath the radar during the current credit squeeze, Abingworth is one of the few that is not just visible but appears to be operating on a business as usual basis. Scrip's biotechnology correspondent Sukaina Virji speaks to managing partner Stephen Bunting.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.